Loading…
Generate Biomedicines, Inc. is projected to rise to $17.26 by 2027, a +21% move from its current price of $14.33. GENB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $13.71 | $14.32 | $14.97 | -0.01% |
| Jul 14 | $13.46 | $14.32 | $15.24 | -0.02% |
| Jul 15 | $13.27 | $14.32 | $15.45 | -0.03% |
| Jul 16 | $13.12 | $14.32 | $15.63 | -0.04% |
| Jul 17 | $12.98 | $14.32 | $15.79 | -0.04% |
| Jul 18 | $12.86 | $14.32 | $15.94 | -0.05% |
| Jul 19 | $12.75 | $14.32 | $16.08 | -0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.75 | $14.32 | $16.08 | -0.06% |
| Week 2 | $12.14 | $14.31 | $16.86 | -0.12% |
| Week 3 | $11.70 | $14.30 | $17.48 | -0.19% |
| Week 4 | $11.33 | $14.29 | $18.02 | -0.25% |
| Week 5 | $11.02 | $14.28 | $18.51 | -0.31% |
| Week 6 | $10.74 | $14.27 | $18.96 | -0.37% |
| Week 7 | $10.50 | $14.26 | $19.38 | -0.43% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Generate Biomedicines, Inc. is a healthcare company focused on generative biology that uses machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development and is based in Somerville, Massachusetts.
The company was incorporated in 2018 and was formerly known as Generate Biologics, Inc., changing its name to Generate Biomedicines, Inc. in February 2020.
Its product portfolio includes GB-0895, an investigational long-acting anti-TSLP monoclonal antibody for severe asthma dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T Cell therapy. Generate Biomedicines also develops the Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies.
GENB is a healthcare stock with a current price of $14.33 and a market cap of $1.84B, ranking 2098 by market capitalization. The latest data show the stock trading at a modest level relative to its market size.
The 30-day forecast for 2026 shows an average price of $14.33 with a low of $11.21 and a high of $18.27, with sentiment listed as NEUTRAL. This provides a near-term frame for expected movement around the current level.
From 2027 onward the forecast turns bullish, with 2027 average $17.28 and 2028 $20.08, rising through 2029 to $27.81 and 2030 to $35.79. The longer-horizon path shows continued upside, with 2031 $36.23, 2032 $42.46, 2033 $45.18, 2034 $42.03, and 2035 $55.66 on average. The 2040 forecast averages $92.68 and the 2050 forecast averages $217.07, with corresponding max values that imply substantial upside over time.
A major floor 36.3% below — a decisive break under it would weaken the trend.
The nearest floor, 16.4% below — buyers have tended to step in here.
The nearest ceiling, 21.5% above — a clean break opens room to run.
A major ceiling 39.7% above — clearing it would confirm fresh momentum.
Key GENB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GENB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $15.81 | Sell | $15.55 | Sell |
| MA 10 | $16.32 | Sell | $15.80 | Sell |
| MA 20 | $15.39 | Sell | $15.46 | Sell |
| MA 50 | $14.40 | Sell | $14.54 | Sell |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.41 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -55.31 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.18 | Sell |
| ROC (12) | -7.13 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.75 | Buy |
| Awesome (5,34) | 1.30 | Buy |
| Ultimate (7,14,28) | 33.56 | Neutral |
| Momentum (10) | -2.09 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 15.15 | Sell |
| ADX (14) | 16.35 | Neutral |
| ATR (14) | 0.59 | Info |
The 30-day technical picture is NEUTRAL, with RSI(14) at 40 and the price hovering near the 50-day simple moving average of $14.40. There is no data for the 200-day moving average in the provided set.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $11.21 | $14.33 | $18.24 | 0% | Neutral | |
| $11.95 | $17.26 | $27.04 | +21% | Bullish | |
| $12.84 | $20.08 | $33.88 | +40% | Bullish | |
| $16.58 | $27.77 | $49.54 | +94% | Bullish | |
| $20.04 | $35.78 | $66.84 | +150% | Bullish | |
| $19.11 | $36.25 | $70.44 | +153% | Bullish | |
| $21.08 | $42.40 | $85.31 | +196% | Bullish | |
| $21.22 | $45.19 | $93.80 | +215% | Bullish | |
| $18.95 | $42.10 | $89.88 | +194% | Bullish | |
| $24.98 | $55.51 | $121.60 | +288% | Bullish | |
| $41.76 | $92.81 | $213.45 | +548% | Bullish | |
| $97.51 | $216.69 | $498.39 | +14.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $11.21 | $14.33 | $17.40 | +0.00% |
| August 2026 | $11.23 | $13.77 | $17.69 | -3.86% |
| September 2026 | $11.38 | $14.21 | $18.72 | +3.18% |
| October 2026 | $11.10 | $14.07 | $18.93 | -0.96% |
| November 2026 | $10.26 | $13.17 | $18.03 | -6.41% |
| December 2026 | $10.09 | $13.12 | $18.24 | -0.41% |
Click any year to see its month-by-month GENB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Generate Biomedicines, Inc.'s 2026 outlook centres on $14.33, within a $11.21 to $18.24 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, GENB could reach as high as $27.04, with a base case around $17.26 and support toward $11.95 — roughly +21% from $14.33. Momentum favours further upside here.
Expect GENB to range from $12.84 to $33.88 through 2028. The $20.08 average target implies a +40% move from current prices. That is up +16% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The GENB price prediction for 2029 points to an average of $27.77 (low $16.58, high $49.54) — a potential gain of +94% on today's $14.33. Momentum favours further upside here.
In 2030, GENB is projected to trade between $20.04 and $66.84, averaging $35.78 — a potential gain of +150% from today's $14.33. That is up +29% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Generate Biomedicines, Inc.'s 2031 outlook centres on $36.25, within a $19.11 to $70.44 range. That is up +1% on the projected 2030 average. That marks a +153% change versus current levels. Momentum favours further upside here.
By 2032, GENB could reach as high as $85.31, with a base case around $42.40 and support toward $21.08 — roughly +196% from $14.33. Buyers look set to stay in control over this stretch.
Expect GENB to range from $21.22 to $93.80 through 2033. The $45.19 average target implies a +215% move from current prices. That is up +7% on the projected 2032 average. Momentum favours further upside here.
The GENB price prediction for 2034 points to an average of $42.10 (low $18.95, high $89.88) — a potential gain of +194% on today's $14.33. Buyers look set to stay in control over this stretch.
In 2035, GENB is projected to trade between $24.98 and $121.60, averaging $55.51 — a potential gain of +288% from today's $14.33. That is up +32% on the projected 2034 average. Momentum favours further upside here.
Generate Biomedicines, Inc.'s 2040 outlook centres on $92.81, within a $41.76 to $213.45 range. That is up +67% on the projected 2035 average. That marks a +548% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, GENB could reach as high as $498.39, with a base case around $216.69 and support toward $97.51 — roughly +14.1x from $14.33. Momentum favours further upside here.
Investing $1,000 in GENB today (≈ 69.808028 GENB) could be worth
$15,126.82
+$14,126.82 (+1413%) by 2050 · US Dollar
Based on the average projected GENB price of $216.69 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GENBwould be worth at today's price.
$1,000 invested in GENB on Feb 27, 2026 (≈ 79.051386 GENB) would be worth
$1,132.41
+$132.41 (+13.2%) today · 1.13× · US Dollar
Based on a GENB entry price of $12.65 vs. today's $14.33.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.41 | $822.8 | -17.7% |
| 1 month ago | $13.16 | $1,088.53 | +8.9% |
| 3 months ago | $11.41 | $1,255.48 | +25.5% |
| All time ago | $12.65 | $1,132.41 | +13.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GENB forecast.
Our base-case forecast reaches $29.00 around 2030.
Implied market cap at $29.00: $3.72B
The multi-year forecast shows a bullish trajectory from 2027 through 2050, with the average price rising from $17.28 in 2027 to $217.07 in 2050. Return expectations rise along with the price, with ROI values climbing from 20.6% in 2027 to 1415.3% in 2050. Max projected prices also extend well beyond current levels, with 2030 max $66.86, 2035 max $121.94, 2040 max $213.16, and 2050 max $499.27.
These figures illustrate the potential upside over the longer horizon, though they are estimates and carry uncertainty.
Tap a question to reveal the answer.
2029 avg $27.81; 2030 avg $35.79 with min $20.04 and max $66.86; ROI 149.8%; sentiment BULLISH.
Forecasts show a bullish trajectory from 2027 onward, with 2050 avg $217.07 and ROI up to 1415.3%, though these are estimates and not guarantees.
Yes. The forecast shows 2035 max $121.94 and 2040 max $213.16, indicating $100 is attainable within the projected range.
Current price is $14.33 and market cap is $1.84B.
The 30-day range is from $10.73 to $19.12.
Generate Biomedicines, Inc. Community Discussion
0Share your Generate Biomedicines, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.